PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) Breaking News - June 14, 2017

PetLife Announces Its All-Natural “Cancer Cocktail” with Applicability to Pet and Human Markets

The Company may be the first to offer an all-natural “cancer cocktail” combining the therapeutic benefits of the plant and animal kingdoms.

HANCOCK, MD - June 14, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually.

PetLife’s new patent-pending formulation has created a “cancer cocktail” combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease to have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing recommended for the treatment of both neoplastic (cancer) and infectious disease. The “HIV Cocktail,” which changed the world approach to the treatment of HIV, is a similar approach comparison. PetLife’s new “cancer cocktail” may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife’s new “cancer cocktail” has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient.

For hundreds, if not thousands of years, plant-based medicinals have formed the foundation of therapeutic treatment in the Chinese, Native American and Ayurvedic traditions. More recently, scientists have discovered the mode of action of many of these therapies. In many cases, the chemical compounds have been manipulated or synthesized to create new chemical entitles (“NCE”). Along with the creation of NCEs comes the inherent risk of unintended consequences and adverse reactions. By maintaining an all-natural formulation, PetLife intends to capture the therapeutic benefit of plant-based therapy without the creation of any unintended consequences. Our team has identified certain phytonutrients which can work synergistically with Blue Scorpion Venom for inhibition of cancer cell growth.

“Our new formulation, RX002CxN, will become the basis of PetLife Pharmaceutical’s new product portfolio, VitalzulTM., a novel treatment option for the treatment of cancer and potentially other indications. The low toxicity of our formulation gives additional benefit. Given the comparative biology of animals and humans, it is our hope that success in treatment of cancer in animals will lead to similar results in humans. Our new formulation has been designed with both human and animal applications in mind. Once testing is completed, the Company will strategically determine the best course of development in both the pet and human markets,” stated Dr. Vivekananda Ramana, Chief Medical Officer of the Company.

“This groundbreaking, patent pending bio technology will serve as the core ingredient in our pharma product Vitalzul™ once we complete the much anticipated FDA trials. It is well known that animal research and studies are the foundation of human applications. Our first goal is to complete the successful testing, FDA application, and commercialization for the benefit of animals. Then, we will move aggressively in expanding our research in the human arena, where we anticipate strong interest from industry leaders,” added Dr. Salvagno.

About PetLife Pharmaceutical
PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul™’s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will launch in 2017. PetLife Scorpion Ranch™ will break ground in 2017. PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Clifford Price
clifford@petlifepharma.com
844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

_____________________________________________________
Recent PetLife Pharmaceuticals News:

PetLife Completes Its TV Commercial for Newly Acquired Dr. Geoff's by PetLife, Preparing for Regional Launch

Clip of TV Commercial at http://www.petlifepharma.com/drg

HANCOCK, MD - June 6, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that its wholly owned subsidiary, Dr. Geoff's by PetLife, Inc. ("Dr. Geoff's by PetLife"), PetLife's product line of natural pet food, supplements, and treats, has initiated its comprehensive product rollout.

The Company, through its wholly owned subsidiary, will proceed with an initial regional pilot launch, followed by a national rollout. The introductory product launch will focus on two Superfood Supplements: ImmunoPower™ and Antioxidant Boost™, and several canned food products, with extensive plans for product line expansion.

ImmunoPower™ is a unique, proprietary blend of micro-ingredients that equips the pet's body with the nutrients to support overall well-being and is formulated to deliver as much antioxidant power as possible.

Antioxidant Boost™ uses the power of antioxidant vitamins, antioxidant chelated minerals, phytonutrients, digestive enzymes and probiotics combined in this unique super-food.

The TV commercial for the product launch has been prepared and completed by a world-class production and media team. Media buys are currently being sourced to provide the best value. For a short segment view of the TV commercial, visit: http://www.petlifepharma.com/drg/. This TV commercial will be incorporated into an infomercial and promoted through social media.

"The strategic advantage of launching our food product in advance of the anticipated FDA approved Vitalzul™ is that it provides the Company the advantage of revenues, profits and enhanced cash flow," stated Dr. Ralph Salvagno, CEO of PetLife. "Brand awareness is a key component for success given the competitive market in the pet food industry. We believe that our core product, Vitalzul™, when infused into pet food, will create an extraordinary, proprietary and world class product for pets and their owners. The Company plans to offer two additional food products infused with Vitalzul™: a veterinary prescribed, therapeutic form for pets with cancer, and a product proposed as a preventive for older dogs. Statistically, 49% of dogs and 38% of cats will be stricken with some form of cancer after the age of 10."

PetLife plans to roll out a complete line of 25 foods, treats, supplements, and pet accessories. These include nutraceuticals, shampoos, creams, sprays, and other natural products for dogs and cats. PetLife is in discussions with third parties to provide specific complementary products that would not be "just another product on the shelf" but those that have proprietary properties that will enhance PetLife's reputation as a quality provider of natural-based solutions for animal diseases and conditions.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, Vitalzul™, is currently in testing. Vitalzul™'s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets, is launching in 2017. PetLife Scorpion Ranch™ is breaking ground in 2017. PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Company Contact
Clifford Price
clifford@petlifepharma.com
844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals Launches New Website

HANCOCK, MD - June 1, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced its new Website, www.petlifepharma.com .

PetLife has launched its new Website to incorporate the Company's recent announcement of its patent filings in the United States and India, as well as more information on the Company's short- and long-term plans, including the establishment of the PetLife Scorpion Ranch™ for Blue Scorpions, and the addition of Dr. Geoff's by PetLife™.

Dr. Ralph T. Salvagno, CEO of PetLife, stated, "Our Website will continue to evolve as activities, specifically the PetLife Scorpion Ranch™, are brought online. We will also be making announcements on the availability to consumers for our premier line of pet food."

The new Website also provides for the biographies of the management team, including Dr. Salvagno, Dr. Vivekananda Ramana, our Chief Medical Officer, and Dr. Joel Beth Mitchell-Navratik, our Director of Veterinary Affairs. Dr. Ramana and his research team are working closely with Dr. Salvagno with our United States Food and Drug Administration ("FDA") application. Dr. Ramana has successfully registered 25 compounds with the FDA. Dr. Mitchell-Navratik, a veterinarian, is a key member of our scientific team.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, Vitalzul™, is currently in testing. Vitalzul's™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLifes's acquired brand, Dr. Geoff's by PetLife™, will launch in 2017. PetLife Scorpion Ranch™ will break ground in 2017. PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLR Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Press Contact
Clifford Price
clifford@PetLifePharma.com
844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Files for Patent for the Treatment of Cancer for Pets

HANCOCK, MD - May 30, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that they have filed for patent protection in India and the United States for the formula for VitalZul™.

The Company, through an officer of the Company, has filed for a patent in India titled, A Composition for Targeting Cancer in Canines and Humans. The patent protection is for both process and composition thus protecting not only the physical elements of our formulation but also the process by which they are combined. The patent formulation is intended for both animal and human use, pending further testing.

The filing in the United States was titled the same as the India patent with the same attributes as filed in India.

The elements of the formulation of VitalZul™ have been shown to have extremely minimal toxicity. The components of the formulation are natural, not synthetic.

Dr. Ralph Salvagno, CEO of PetLife, stated, "Our team of scientists and researchers in India and in the U.S. have worked diligently to bring VitalZul™ to the next stage of our growth plan. With the patents filed, we will continue the course towards our FDA application. The goal is to bring VitalZul™ to market by the end of 2018."

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology, with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, VitalZul™, is currently in testing. VitalZul's™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward-Looking Statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLR Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact
Clifford Price
Clifford@PetLifePharma.com
844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Management Comments on Recent Market Activity

HANCOCK, MD - May 28, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced the Company's comments on recent developments in its stock price and trading performance.

The Company is confident that the main reason of the investors' interest in its stock is our business performance, which is reflected on the Company's website and its press releases (http://www.petlifepharma.com/investor-relations/), as well as has been presented to numerous investors during road shows conducted by the Company in several cities. We have been pleased to announce a string of positive developments with our business, which we believe to have been the procuring cause of investors' buying our stock at or about the times when the Company announced such good business-related news or has investor presentations. At the same time, we became aware of the efforts to promote our stock by various penny stock-touting websites, newsletter publishers and IR marketing services, unknown to and unaffiliated with the Company. We first noticed that activity in February 2017, and observed the same type of efforts recently.

It is our understanding that such promotional activities happen when companies quoted on OTC Markets publish news, which cause the prices of their respective stocks to move. Third party stock promoters scan the market, mention stocks, which they find on the move, to their subscribers, claim credit for such moves, and solicit payments from both subscribers and others.

We do not believe that such promotional activities unauthorized, unrelated to, and not approved by the Company, can cause a significant number of investors to buy our stock. We strongly believe that the main reasons for the investors buying the stock of our Company have been our business performance reflected in press releases and presented to multiple accredited investors during our road shows. Unfortunately, the activities of third party stock promoters seeking to exploit positive developments in our business and appreciation of our stock price have a clear adverse effect on our stock price as follows. Apparently, market makers engaged in predatory short selling are among the most active subscribers to the services of such stock promoters. For example, our stock price moved up recently as the result of the positive press release published on May 23, 2017. That was picked up and exploited by some stock-touting websites and already on May 25, 2017 (according to FINRA's web page tracking the short-selling at http://regsho.finra.org/FORFshvol20170525.txt), 226,257 shares of our stock were sold short in one day. That is 60% of the daily volume of trading on that date. We have also observed what appears to be a very active short-selling activity on May 26, 2017, when another positive press release caused our stock price to move up. The Company may be addressing this with the market regulators, including naming the most active short-selling market makers, in a hope that both OTC Marketplace and FINRA interfere with their predatory market price manipulations.

It is our obligation to OTC Marketplace and the investors to hereby state that after inquiry of the Management of the Company, we have determined that the directors, control persons, its officers, directors, or any controlling shareholders (defined as shareholders owning 10% or more of the Company's securities) have not, directly, or indirectly, been involved in any way (including payment of a third-party), with the creation or distribution of promotional materials related to the Company and its securities. Furthermore, after inquiry of management, we have determined that the directors and control persons, the Company, its officers, directors or any controlling shareholders have sold or purchased the Company's securities within the past 90 days.

In order to further address the concerns related to the unauthorized promotional activities the Company will be putting out a SEC Form 8-K enumerating all the relevant press releases as well as naming the list of third party providers engaged by the Company to provide investor relations services, public relations services, marketing, or other related services, including the promotion of the Company or its securities, since January 1, 2016. We are also planning to address in the same SEC Form 8-K filing, the detailed information about shares or convertible instruments issued by the Company allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.

Furthermore, the Company needs to draw attention of some materially inaccurate and outdated information, which has been included in the unauthorized and unapproved disseminations. In particular, the mentioning of "Gain" of 349% relating to a historical stock price is materially incorrect as it fails to account for a 5:1 reverse merger that occurred during the interval in question. Additionally, as part of our negotiations with our former CEO, we have removed all mentions of Escozine from the approved Company literature, including any claims made by the manufacturer of Escozine. The Company abandoned the use of the term "organic" in its authorized publications. The use of the term "Escozine for Pets" was abandoned by the Company in favor of VitalzulTM. The Company does not currently describe its products as "a preventative and treatment for cancer." Additionally, the Company has no opinion on the accuracy of any technical analysis represented in some unauthorized disseminations. No technical analysis has been performed by the Company regarding its stock.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, VitalZul™, is currently in testing. VitalZul's™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLR Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact:
Clifford Price
Clifford@PetLifePharma.com
844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Explores New Scorpion Venom-Based Therapies for Growing Product Line

HANCOCK, MD - May 26, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that they are exploring various new products for their product line.

PetLife research has verified that scorpion venoms may also have antibacterial and anti-inflammatory properties. The action of most venoms may be due to the primary toxin but, also is likely influenced by other components in the venom. These components, even in small quantities, may hold the key to the true action of scorpion venom. The advantages of using natural venom, as opposed to synthetic venom, is that all components of the venom are included in the therapeutic formulation. The effect of certain venoms as anti-tumor agents has been cited in the literature. Aside from the known anti-tumorigenic action of the primary toxin, other components of the venom may explain the venom's action on other disease state cells. The PetLife research team is evaluating the potential for scorpion venom-based therapy for common companion pet diseases, such as Lyme disease and arthritis.

Dr. Ralph Salvagno, CEO of PetLife, stated, "Traditionally, research in scorpion venom therapy has centered around the treatment of 'envenomation,' which is the scientific name for scorpion stings. Our research team recognizes the potential benefit of scorpion venom for the treatment of significant medical conditions that affect our pets and will continue with their research in this field. We hope to be able to add non-toxic natural-based treatment for several diseases to our portfolio in the future."

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, VitalZul™, is currently in testing. VitalZul's™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward-Looking Statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLR Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact
Clifford Price
clifford@PetLifePharma.com
844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Closes Acquisition of Assets for Dr. Geoff's Real Food for Pets

The product line is projected to include VitalZul™ in a second generation of the product in 2018

HANCOCK, MD - May 23, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that its subsidiary, Dr. Geoff's by PetLife, Inc. ("Dr. Geoff's by PetLife"), has completed the acquisition of assets related to the natural pet food product line.

The various trademarks supporting the Dr. Geoff's Real Food for Pets™ were acquired in exchange for common stock of the Company.

The Company, through its subsidiary, will implement its plans for a national rollout to the public in the latter part of 2017. The initial flow of products includes canned food and two Superfood Supplements, ImmunoPower™ and Antioxidant Boost™, which should have many benefits for companion pets. PetLife will, over time, roll out a complete product line of 25 foods, treats, supplements, and pet accessories. These include nutraceuticals, shampoos, creams, sprays, and other natural products (i.e. supplements) for dogs and cats.

PetLife projects the inclusion of VitalZul™, the Company's patent pending, non-toxic, bioactive formulation, into a second-generation line of pet food. The active ingredients of VitalZul™ have been shown to have activity against several different cancer cell lines.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, VitalZul™, is currently in testing. VitalZul's™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact
Clifford Price
clifford@PetLifePharma.com
844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals Engages Carter, Terry & Company for Financing of FDA Application

HANCOCK, MD - May 16, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has engaged Carter, Terry & Company ("Carter Terry"), a full-service investment brokerage, investing banking, asset management, and banking services firm, to help finance the development of PetLife's product development and research to fight cancer in pets and the FDA application. The Company seeks to raise $4 million in this series of financing.

"The funds raised will significantly progress the Company toward bringing VitalZul™ to our customers, the families of pets with cancer," said Dr. Ralph Salvagno, CEO of PetLife Pharmaceuticals. "Our Company is at the forefront of the fight against cancer in pets, and this round of fundraising is a vote of confidence in our product and company vision."

Founded in 1985 and headquartered in Atlanta, Georgia, Carter Terry has had a consistent pattern of dynamic growth. Carter Terry is a member of the Financial Industry Regulatory Authority ("FINRA"), the Securities Industry Association, and the Securities Investor Protection Corporation.

For more information about Carter Terry, please visit: www.carterterry.com.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company. PetLife's mission is to bring new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, VitalZul™, is currently in testing. VitalZul's™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

About Carter, Terry, & Company

Founded in 1985, Carter, Terry & Company is a full-service investment brokerage, investment banking, asset management and banking services firm that has a consistent pattern of dynamic growth. They are currently one of the largest independent firms in Atlanta, serving clients throughout the country.

Forward looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact
Clifford Price
clifford@PetLifePharma.com
844-473-8543 ext 701

SOURCE: PetLife Pharmaceuticals, Inc.
 

For additional news please go to:  https://www.otcmarkets.com/stock/PTLF/news

-------------------------------------------------------------------
About PetLife Pharmaceuticals, Inc.:

The Company

PetLife Pharmaceuticals, Inc. is a registered U.S. Veterinary Pharmaceutical company whose mission is to bring its scientifically proven, bioactive medication and nutraceuticals -- “Vitalzul™” -- to the world of veterinary oncology. The Company specializes in the research, development, sales and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis.

PetLife Pharmaceuticals, Inc. (“Petlife” with the trading symbol OTCQB: PTLF) has developed a new advanced generation of potentiated veterinary cancer medications and nutraceuticals based on the Company’s formula of Blue Scorpion venom and other natural compounds.

Petlife's products have shown the potential to prevent and treat cancer, as well as to dramatically improve quality of life and extend the longevity of pets with cancer. This is accomplished without the harmful side effects of conventional chemotherapy and other traditional treatment programs. Nutraceuticals, food, pet treats, and the anticipated registration of an FDA approved drug for the treatment of cancer in animals are all in the works today.

PetLife is building a team of industry leaders with the primary goal of diversifying its core product line. There are many opportunities available in the pharmaceutical space for introducing new and improved drugs to treat the most common diseases facing our companion pets and animals today. PetLife’s mission is to identify, perfect, and bring these opportunities to market with the goal of improving the quality of life in our companion animals.

What will the Company do?

PetLife, which the name defines the intent of the Company, plans to address cancer in dogs and cats. Many pet owners have already dealt with cancer and their beloved pet. PetLife, managed by pet lovers, desires to provide pet owners options to prevent and/or assist with, cancer in their pet.

Most people grew up with a pet and still have a pet. Pet owners, as the marketplace indicates strongly, will do anything for their pet. If PetLife can provide quality of life for the pet suffering, even prolonging life with quality, much less help prevent potential cancer, then the Company, its management, and its shareholders will benefit in two ways: 1) helping pet owners and their pet, and 2) creating a success, job creating company that will be respected in the industry.

The PetLife Team

The management of the Company is Ralph T. Salvagno, MD (Chief Executive Officer), Dr. Vivek Ramana (Chief Medical Officer), and Clifford H. Price (Vice President of Sales & Marketing).

Operations and Manufacturing The Company uses a manufacturing facility that is certified in CMC (certified manufacturing control), GMP (good manufacturing practice), GLP (good laboratory practice) under international guidelines meeting FDA (United States Food and Drug Administration) standards.

The Science

For millennia, the scorpion has been steeped in mystery. The pursuit of its secret healing properties has been the focus of many generations.

From scorpion fossils in the Silurian period, 430 million years ago, to the Pharaohs and Chinese dynasties to Cuban and Dominican traditional remedies, scorpion venom is now the focus of today’s modern, scientifically based research across the globe. The interest has been so great that several EU countries formed Venomics, sponsored by the French government to specifically study and identify the therapeutic possibilities of all known venoms including Scorpion Venom.

The University of Chicago, Cedars Sinai in Los Angeles, Cornell University, Michigan State University and the University of Washington have extensively researched the therapeutic effects of scorpion venom.

Scientists at PetLife have taken this research to another level. Instead of separating the single molecule from the original complex natural structure and synthesizing it, our scientists decided to keep the scorpion peptide in its original form since the mechanism of action of the scorpion venom is multi-dimensional and complex.

Since the histology (cellular biology) of humans, dogs and cats is quite similar at the molecular level, and given the growing body of new preclinical research demonstrating the effectiveness of polarized scorpion venom in human malignancy, many companion animal owners as well as veterinarians have been drawn to use Vitalzul for Pets™.

Applying science to discover therapies that significantly improve
and extend pets lives.

How many companion animals are diagnosed with cancer each year?
It is estimated that 70-80 million dogs and 74-96 million cats are owned in the United States.

Every day 10,000 dogs and 6,000 cats are diagnosed with cancer.

PetLife Pharmaceuticals, Inc. (PTLF) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul’s™ active ingredients have been shown to have activity against several different cancer cell lines.

Important Facts to Know

• 1/4 of dogs and 1/5 of cats will develop cancer in their lifetime!
• Cancer is the #1 disease related cause of death in dogs in the US
• Cancer accounts for almost 50% of deaths in pets older than 10 years old
• Conventional treatment can cost SEVERAL thousands of dollars, forcing pet owners to watch their pet slowly deteriorate

New frontier in pet oncological treatment utilizing the venom of the Blue Scorpion

PetLife Pharmaceuticals is introducing a new breakthrough pet cancer drug that is anticipated to begin FDA trials in the upcoming months. The drug is an all-natural compound. The FDA trials are estimated to take approximately 18-24 months. PetLife Pharmaceuticals, Inc. is a publicly traded company. The stock symbol is PTLF on the OTCQB market. PetLife is a new biotech company developing products to address disease in our companion pets.

VET ENDORSEMENTS

Dr. Joel Beth Mitchell-Navratik

Bootsy is almost 17 years old and I have been treating her since she was an 8-week-old kitten. In July 2014 Bootsy came in for not feeling well and she had labored breathing. Chest radiographs showed a large pulmonary mass.

Bootsy also has well controlled hyperthyroidism, hypertrophic cardiomyopathy and chronic renal disease. At the time of diagnosis, Bootsy was almost 15 years old. Based on additional diagnostics including, and abdominal ultrasound, and other laboratory tests, the tumor appeared to only be in the lung lobe and had not yet spread. I had given her a few months to live. Needless to say, Ms. Blessing was devastated. All of the current treatment options which included a thoracotomy to remove the lung lobe, chemo or radiation were all more than what the owner wanted. Ms. Blessing did not want to pursue surgery due to her advanced age and multiple health issues, and did not want to do chemotherapy due to the possible side effects.

She inquired about alternative treatment and an associate of mine prescribed some Chinese herbs, but she did not tolerate them well. A few days later she had an episode of heavy breathing again and Flovent was initiated. In late August, she was not eating well and displayed signs of nausea and she was started on nausea medicine and appetite stimulants. The owner was considering euthanasia.

In Mid-September, I learned about Vitalzul™ and offered for her to be a part of our anecdotal clinical trial. We repeated radiographs that week and the tumor size had not changed. Radiographs were repeated on November 2nd and the masses appeared smaller radiographically, which was only 7 weeks after starting Vitalzul™. We repeated radiographs again on 11/26/15 to make sure the previous radiograph was not distorted due to positioning. Again, the radiographs showed the tumor was smaller. Radiographs were taken 12/9/14 and 10/15/16 and 10/26/15 and all show the tumor to be smaller.

The tumor was not gone but smaller. Bootsy has been on Vitalzul™ twice daily for over 2 years and has serial exams and chest radiographs. She has a good quality of life and is doing well today. Bootsy is also taking multiple other medications without apparent drug interactions which include Methimazole, Atenolol, Flovent, Cerenia, Zoran and k/d diet and she has not suffered the typical side effects of chemotherapy.

We will be continuing her VitalZul for Pets™ and following her progress. Aventura Animal Hospital & Pet Resort is a full-service veterinary medical facility located in Aventura, Florida.

Before Treatment with Vitalzul™ for Pets Noticeable soft tissue pulmonary infiltrate

One Week After Treatment with Vitalzul™ for Pets Soft tissue pulmonary infiltrate has begun to show signs of reduction

Seven Weeks After Treatment with Vitalzul™ for Pets Dramatic decrease in soft tissue pulmonary infiltrate

DR. JOEL BETH MITCHELL-NAVRATIK
VETERINARY AFFAIRS

Dr. Mitchell-Navratik holds a Bachelor of Science Degree in Zoology and a Doctorate in Veterinary Medicine from the University of Florida. After university, she undertook an internship in Small Animal Medicine and Surgery at The Animal Medical Center and Bobst Hospital in New York City in 1994. That same years, she joined the Aventura Animal Hospital and was soon promoted to the position of Chief of Staff within the facility. This is a position she has held ever since.

One of her biggest achievements at the facility has been to expand Aventura Animal Hospital to a full-service hospital with an emergency care unit that is open 24 hours a day, 7 days a week. Since 2001, Dr. Joel Beth Mitchell-Navratik has served as the Corporate Medical Director for Pet Medical Centers, LLC. in South Florida. Pet Medical Centers is comprised of 8 state of the art small animal veterinary hospitals employing 27 veterinarians and 162 staff members. Pet Medical Centers offers a comprehensive approach to Veterinary Care, which includes internal medicine, surgery, radiology, ultrasound, CT imaging, boarding, grooming, preventive medicine, and a fully stocked pharmacy. Pet Medical Centers is the largest privately held group of veterinary hospitals in the Unites States.

SOURCE: http://petlifepharma.com/

Disclaimer